EXFORGE HCT 10/160/12.5 * SATCHET is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan, and hydrochlorothiazide are taken either as three single component formulations or as a dual-component formulation with a single component formulation, all components at the same dose level.